Equities research analysts expect bluebird bio Inc (NASDAQ:BLUE) to post sales of $10.33 million for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for bluebird bio’s earnings, with the lowest sales estimate coming in at $5.00 million and the highest estimate coming in at $12.00 million. bluebird bio posted sales of $4.17 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 147.7%. The business is scheduled to issue its next earnings report on Wednesday, February 20th.

According to Zacks, analysts expect that bluebird bio will report full-year sales of $44.33 million for the current financial year, with estimates ranging from $37.00 million to $48.00 million. For the next fiscal year, analysts forecast that the business will post sales of $72.97 million, with estimates ranging from $55.67 million to $121.59 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for bluebird bio.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, topping analysts’ consensus estimates of ($2.90) by $0.17. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The business had revenue of $11.50 million during the quarter, compared to the consensus estimate of $6.90 million. During the same period in the prior year, the firm posted ($1.73) EPS. The business’s revenue for the quarter was up 49.2% on a year-over-year basis.

Several analysts recently issued reports on the company. Piper Jaffray Companies downgraded bluebird bio from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $240.00 to $120.00 in a report on Thursday. Oppenheimer reiterated a “hold” rating on shares of bluebird bio in a report on Tuesday. William Blair reiterated a “buy” rating on shares of bluebird bio in a report on Tuesday. Janney Montgomery Scott set a $170.00 price target on bluebird bio and gave the company a “buy” rating in a report on Monday. Finally, Maxim Group reiterated a “hold” rating on shares of bluebird bio in a report on Monday. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and seventeen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $194.80.

In other bluebird bio news, insider Jeffrey T. Walsh sold 1,500 shares of the company’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $150.16, for a total value of $225,240.00. Following the completion of the transaction, the insider now directly owns 36,995 shares of the company’s stock, valued at approximately $5,555,169.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David Davidson sold 5,000 shares of the company’s stock in a transaction dated Tuesday, October 2nd. The shares were sold at an average price of $139.32, for a total transaction of $696,600.00. Following the completion of the transaction, the insider now directly owns 29,905 shares of the company’s stock, valued at $4,166,364.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 21,490 shares of company stock valued at $2,901,186. 3.00% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of BLUE. Stratos Wealth Partners LTD. bought a new position in shares of bluebird bio during the third quarter worth about $106,000. Belpointe Asset Management LLC bought a new position in shares of bluebird bio during the third quarter worth about $110,000. NuWave Investment Management LLC lifted its position in shares of bluebird bio by 10,811.1% during the third quarter. NuWave Investment Management LLC now owns 982 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 973 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of bluebird bio by 635.0% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,154 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 997 shares during the last quarter. Finally, Tower Research Capital LLC TRC bought a new position in shares of bluebird bio during the second quarter worth about $201,000.

NASDAQ BLUE traded down $4.80 during trading hours on Monday, hitting $108.85. The company had a trading volume of 1,221,722 shares, compared to its average volume of 793,337. bluebird bio has a fifty-two week low of $100.99 and a fifty-two week high of $236.17. The company has a market cap of $6.22 billion, a P/E ratio of -14.12 and a beta of 2.37.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Featured Article: Fundamental Analysis and Individual Investors

Get a free copy of the Zacks research report on bluebird bio (BLUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.